A new study in The Lancet Public Health found that early COVID-19 test development and distribution saved millions of lives. The COVID-19 pandemic highlighted how crucial testing is for disease preparedness and response, and new research from the Johns Hopkins Applied Physics Laboratory (APL) and a team of collaborators underscores that principle. Published in the
Long-term monitoring and management of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks. In a population-based study published in JAMA Dermatology, researchers from the Republic of Korea investigated whether having a history of coronavirus disease 2019 (COVID-19) increased the long-term risk of autoimmune and autoinflammatory connective tissue disorders.
A study today in JAMA suggests that hospitalized patients—primarily previously healthy young men—have considerably fewer cardiovascular sequelae by 18 months if they develop myocarditis after COVID-19 mRNA vaccination than after COVID-19 infection. French researchers mined data from the French National Health Data System on all 4,635 residents aged 12 to 49 years hospitalized for myocarditis, or inflammation of the heart
Risk of new diabetes diagnosis was higher compared with non-COVID respiratory infections Children and teens had an increased risk of being diagnosed with type 2 diabetes after COVID-19 infection, a retrospective cohort study of over 600,000 youth suggested. Adolescents 10 to 19 years old had a 55% higher risk for a new diagnosis of type
Authors say findings support considering convalescent plasma deployment for future infectious diseases emergencies A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent plasma had been used more broadly, particularly in outpatients
Research analysis reveals risk of cardiac events also varied by blood type and stays elevated for years after diagnosis A history of COVID-19 can double the risk of heart attack, stroke or death according to new research led by Cleveland Clinic and the University of Southern California. The study found that people with any type of COVID-19
Researchers isolated SARS-CoV-2 strains, which are drug resistant with mutations to the nsp12 protein that is the target of remdesivir and another variant with mutations to the nsp5 protein, the target of Paxlovid. These mutations help the virus persist in people with compromised immunity despite common antiviral treatments. Individuals with compromised immunity and persistent COVID-19
Fibrin (red) and toxic microglia (green) in the brain of a mouse infected with COVID-19. Image courtesy of Jae Kyu Ryu and Katerina Akassoglou. In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that
Candidate vaccine could provide enhanced breadth of protection against emerging SARS-CoV-2 variants. A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. The National
Using single-cell sequencing technology, researchers provide the most comprehensive timeline to date of how the body responds to SARS-CoV-2 exposure. Scientists have discovered novel immune responses that help explain how some individuals avoid getting COVID-19. Using single-cell sequencing, researchers from the Wellcome Sanger Institute, University College London (UCL), Imperial College London, the Netherlands Cancer Institute
